A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BMS986165 in Adolescent Subjects with Moderate to Severe Plaque Psoriasis

This study will be a multi-center, randomized, double-blind, placebo controlled study, to evaluate the efficacy and safety of BMS-986165 in adolescent subjects ages 12 to < 18 years.

This study will consist of two parts and the study participation is approximately up to 66 weeks for each part. Both parts will be divided into the following periods: screening (up to 6 weeks), treatment (52 weeks), and safety follow-up at 4 weeks and 8 weeks.